Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AER Compliance Will Require Preparation, Preparation, Preparation – AHPA

This article was originally published in The Tan Sheet

Executive Summary

Some dietary supplement firms plan to hire contractors to handle consumers' adverse event reports, but most firms will not need outside help if they properly prepare for collecting AERs, industry experts said during a training seminar Feb. 22

You may also be interested in...



Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar

The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law

Homeopathics, Supplements, OTC Medicines Overlap In Pharmacists’ ‘Over-The-Counter’ Survey

Results of U.S. News & World Report’s first “Best OTC Medicine & Health Products” survey include homeopathic formulations, supplements and non-drug topicals in same categories of indications with nonprescription pharmaceuticals.

NMN Supplement Firm Works On Disclosing Sales Relationships With Advertising Affiliates

Renue By Science agrees with National Advertising Division recommendations to “clearly and conspicuously disclose” material connections in online advertising by employees, nonprofits and others offering sales to its supplements containing nicotinamide mononucleotide, quercetin or resveratrol.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel